Last reviewed · How we verify
Latuda (Lurasidone)
Latuda (Lurasidone) is a Atypical antipsychotic Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved for Schizophrenia, Bipolar I disorder depression, Major depressive disorder (adjunctive treatment). Also known as: Lurasidone, Latuda.
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain to reduce psychotic symptoms and mood disturbances.
Latuda (Lurasidone) is a small molecule used to treat schizophrenia. It has been studied in clinical trials as a treatment for schizophrenia, often compared to placebo and other medications such as Risperidone.
At a glance
| Generic name | Latuda (Lurasidone) |
|---|---|
| Also known as | Lurasidone, Latuda |
| Sponsor | Massachusetts General Hospital |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lurasidone acts as an antagonist at dopamine D2 receptors, which are overactive in psychotic disorders, and also blocks serotonin 5-HT7 receptors. This dual mechanism helps reduce positive symptoms (hallucinations, delusions) and may improve mood and cognitive function. The drug has high receptor selectivity and lower affinity for histamine and muscarinic receptors, which may contribute to a favorable side-effect profile compared to older antipsychotics.
Approved indications
- Schizophrenia
- Bipolar I disorder depression
- Major depressive disorder (adjunctive treatment)
Common side effects
- Akathisia
- Somnolence
- Parkinsonism
- Nausea
- Agitation
- Tremor
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression (PHASE2, PHASE3)
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Sleep Quality, Cognitive Performance, and Computerized Cognitive Training
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Latuda (Lurasidone) CI brief — competitive landscape report
- Latuda (Lurasidone) updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about Latuda (Lurasidone)
What is Latuda (Lurasidone)?
How does Latuda (Lurasidone) work?
What is Latuda (Lurasidone) used for?
Who makes Latuda (Lurasidone)?
Is Latuda (Lurasidone) also known as anything else?
What drug class is Latuda (Lurasidone) in?
What development phase is Latuda (Lurasidone) in?
What are the side effects of Latuda (Lurasidone)?
What does Latuda (Lurasidone) target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor, Serotonin 5-HT7 receptor
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar I disorder depression
- Indication: Drugs for Major depressive disorder (adjunctive treatment)
- Also known as: Lurasidone, Latuda
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing